Professor Brian Houston BSc, PhD, DSc
Professor of Drug Metabolism and Pharmacokinetics
- Email: email@example.com
- Telephone: +44 (0)161 275 2358
- Fax: +44 (0)161 275 8349
Manchester Pharmacy School
Room 3.33, Stopford Building
Director of Centre for Applied Pharmacokinetic Research and Group Leader of Drug Metabolism and Pharmacokinetic Research Group and Head of Pharmaceutical Sciences in Manchester Pharmacy School .
The Centre for Applied Pharmacokinetic Research (CAPKR) provides an international lead in the development, evaluation and implementation of in vitro and in silico approaches for predicting human pharmacokinetics. Pharmacokinetics plays a pivotal role in drug discovery, development and use since it widely recognised that being bioactive is not enough to ensure therapeutic success. Knowledge on how a drug enters and is processed by the body is as critical as knowledge as its interaction with target sites. Even today many promising drug candidates fail to make it through drug development due to poor pharmacokinetic properties such as inadequate absorption, poor stability, excessive interaction with other drugs. Other drugs are prematurely withdrawn from the market due to toxicities arising from pharmacokinetic idiosyncrasies.
CAPKR’s aim is to improve prediction at all steps between drug discovery and use with mechanism-based modelling methodologies. Major advances have been made in delineating the science that underpins the development and evaluation of paradigms for human prediction. Research activities include, prediction of drug metabolic clearance, molecular and kinetic basis of drug-drug interactions, pharmacokinetic and statistical modelling. Our use of human tissue, and validated surrogates such as recombinant proteins together with computer simulation and modelling are in sympathy with the current ethical and political pressures to reduce, refine and replace the use of animals in research.
Prediction of Drug Clearance in Humans
Drug metabolism and pharmacokinetics (DMPK) play a pivotal role in drug discovery, development and use. Often drug development is halted or use limited by poor PK properties, mainly drug clearance. We are developing paradigms for the quantitative prediction of human drug clearance through the comprehensive use of different in vitro systems to delineate interactions between the cytochrome P450 and UDP-glucuronyltransferase enzymes and other cellular processes (including permeability and transporter properties). We are particularly interested in the atypical kinetics shown by CYP3A enzymes, the need to incorporate variability and uncertainty within the extrapolation process and transporter-mediated clearance.
Molecular and kinetic basis of Drug-Drug Interactions
In the era of polypharmacy, drug-drug interactions are of major concern and continue to result in drugs being within drawn from the commercial market. We are interested in inhibition of CYP enzymes as the major cause of drug-drug interactions and the ability of simple in vitro systems to predict this effect. We are assessing the modelling of time dependent inhibition, multiple DDIs, transporter involvement and induction effects.
- Drug Toxicity
- Drug Metabolism and Disposition
Brian obtained his BSc, PhD and DSc from the Universities of London (Queen Mary College), Surrey and Manchester, respectively. He is currently Professor of Drug Metabolism and Pharmacokinetics within the School of Pharmacy and Pharmaceutical Sciences. His research is sponsored by a number of sources including the pharmaceutical industry, BBSRC, DoH and the EU.
Brian is Director of the Centre for Applied Pharmacokinetic Research within the School of Pharmacy. This involves four faculty members and supports twenty research staff. As a consortium it operates in collaboration with, and financially supported by five international pharmaceutical companies. All research is generic and involves the prediction of human pharmacokinetics.
Brian is a member of the editorial boards of several scientific journals, has experience on national science funding bodies and is a consultant to a number of pharmaceutical companies.
In recent years he has been particularly active through his research and numerous conference presentations in promoting the use of in vitro and in silico systems for predicting human metabolism and pharmacokinetics.
- 1997 - DSc (Manchester)
- 1973 - PhD (Surrey)
- 1970 - BSc (Queen Mary College, London)
Collaborators and affiliated staff
Frauke Assmus, Tom de Bruyn
A Ufuk, R Sullivan, F Wood and J Harrison
J B Houston. (2014).
Interplay between enzymes and transporters in defining hepatic drug clearance and intracellular concentration of drugs. Presented at Invited talk at The Royal Society of Chemistry. London. eScholarID:220292
Dennis Smith, Per Artursson, Alex Avdeef, Li Di, Gerhard F. Ecker, Bernard Faller, J. Brian Houston, Manfred Kansy, Edward H. Kerns, Stefanie D. Krämer, Hans Lennernäs, Han van de Waterbeemd, Kiyohiko Sugano, and Bernard Testa. (2014).
Passive Lipoidal Diffusion and Carrier-Mediated Cell Uptake Are Both Important Mechanisms of Membrane Permeation in Drug Disposition. Mol Pharm, 11, 1727-1738. eScholarID:229776 | DOI:10.1021/mp400713v
Gertz M, Tsamandouras N, Säll C, Houston JB, Galetin A. (2014).
Reduced Physiologically-Based Pharmacokinetic Model of Repaglinide: Impact of OATP1B1 and CYP2C8 Genotype and Source of In Vitro Data on the Prediction of Drug-Drug Interaction Risk. Pharm Res, eScholarID:225480 | DOI:DOI 10.1007/s11095-014-1333-3
Haruka Nishimuta, J B Houston and Aleksandra Galetin. (2014).
Hepatic, intestinal, renal and plasma hydrolsis of prodrugs in human, cynomolgus monkey, dog and rat - implications for in vitro-in vivo extrapolation of clearance of prodrugs. D M D, eScholarID:229774 | DOI:10.1124/dmd.114.057372
Nishimuta H, Houston JB, Galetin A. (2014).
.Hepatic, intestinal, renal, and plasma hydrolysis of prodrugs in human, cynomolgus monkey, dog, and rat: implications for in vitro-in vivo extrapolation of clearance of prodrugs. D M D, 42(9), 1522-1531. eScholarID:246185 | DOI:doi: 10.1124/dmd.114.057372
A Ufuk, M Gertz, J Plumb, G Somers, JB Houston and A Galetin. (2013).
Drug accumulation in alveolar macrophages: assessment of uptake and lysosomal distribution in vitro. Presented at DMDG. Cambridge, UK. eScholarID:220296
J B Houston. (2013).
Addressing the challenges of low clearance. Presented at Mini Symposium, AAPS Annual Meeting and Exposition. San Antonio, Texas. eScholarID:220286
J B Houston. (2013).
Evaluation of novel in vitro systems for low hepatic clearance and assessment of their predictive utility. Presented at AAPS Annual Meeting and Exposition. San Antonio, Texas. eScholarID:220287
Gill KL, Gertz M, Houston JB, Galetin A. (2013).
Application of a Physiologically-Based Pharmacokinetic Model to Assess Propofol Hepatic and Renal Glucuronidation in Isolation; Utility of In Vitro and In Vivo Data. Drug Metab Dispos. doi:10.1124/dmd.112.050294, 41, 744-753. eScholarID:189684
M Gertz, C Cartwright, M Hobbs, K Kenworthy, M Rowland, JB Houston and A Galetin. (2013).
Cyclosporine inhibition of hepatic and intestinal CYP3A4, uptake and efflux transporters: Application of PBPK modeling in the assessment of drug-drug interaction potential. Pharm Research doi: 10.1007/s11095-012-0918-y, 30(3), 761-780. eScholarID:179761
JB Houston. (2013).
Special Section on Prediction of human pharmacokinetic parameters from in vitro systems-Commentary. Drug Metab Dispos, 41, 1973-1974. eScholarID:220295
Burt HJ, Pertinez H, Säll C, Collins C, Hyland R, Houston JB and Galetin A. (2012).
Emilie Jigorel and J. Brian Houston. (2012).
Utility of Drug Depletion-Time Profiles in Isolated Hepatocytes for Accessing Hepatic Uptake Clearance: Identifying Rate-Limiting Steps and Role of Passive Processes. DRUG METABOLISM AND DISPOSITION, 40(8), 1596-1602. eScholarID:176783 | DOI:10.1124/dmd.112.045732